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ABSTRACT Group II metabotropic glutamate receptors (mGluR2 and mGluR3,
also called mGlu2 and mGlu3, encoded by GRM2 and GRM3, respectively) are thera-
peutic targets for several psychiatric disorders. GRM3 may also be a schizophrenia
susceptibility gene. mGluR2
 /  and mGluR3
 /  mice provide the only unequivocal
means to differentiate between these receptors, yet interpretation of in vivo ﬁndings
may be complicated by secondary effects on expression of other genes. To address this
issue, we examined the expression of NMDA receptor subunits (NR1, NR2A, NR2B)
and glutamate transporters (EAAT1-3), as well as the remaining group II mGluR, in
the hippocampus of mGluR2
 /  and mGluR3
 /  mice, compared with wild-type con-
trols. mGluR2 mRNA was increased in mGluR3
 /  mice, and vice versa. NR2A mRNA
was increased in both knockout mice. EAAT1 (GLAST) mRNA and protein, and
EAAT2 (GLT-1) protein, were reduced in mGluR3
 /  mice, whereas EAAT3 (EAAC1)
mRNA was decreased in mGluR2
 /  mice. Transcripts for NR1 and NR2B were
unchanged. The ﬁndings show a compensatory upregulation of the remaining group II
metabotropic glutamate receptor in the knockout mice. Upregulation of NR2A expression
suggests modiﬁed NMDA receptor signaling in mGluR2
 /  and mGluR3
 /  mice, and
downregulation of glutamate transporter expression suggests a response to altered syn-
aptic glutamate levels. The results show a mutual interplay between mGluR2 and
mGluR3,and also provide acontext in which tointerpret behavioral and electrophysiolog-
ical resultsin these mice.Synapse 62:842–850, 2008. V V C 2008 Wiley-Liss, Inc.
INTRODUCTION
Group II metabotropic glutamate receptors com-
prise mGluR2 (mGlu2, encoded by GRM2) and
mGluR3 (mGlu3, encoded by GRM3). Both are G-pro-
tein coupled receptors, whose activation inhibits ade-
nylate cyclase and decreases cAMP formation. Their
primary functions are thought to be as inhibitory
autoreceptors and thence modulation of glutamatergic
signaling (Anwyl, 1999; Cartmell and Schoepp, 2000);
they also act as heteroceptors modulating the release
of other transmitters including dopamine and GABA.
There is considerable psychiatric interest in these
receptors, for two main reasons. First, they are thera-
peutic targets for several disorders (Harrison, 2008;
Moghaddam, 2004; Swanson et al., 2005), with recent
clinical trials showing positive results in schizophre-
nia (Patil et al., 2007) and in generalized anxiety dis-
orders (Dunayevich et al., 2007). Second, mGluR3 is a
putative candidate gene for schizophrenia and is
implicated in its pathophysiology (Corti et al., 2007a;
Egan et al., 2004; Harrison et al., in press; Sartorius
et al., 2008; Tan et al., 2007) as part of a broader glu-
tamatergic dysfunction (Harrison and Weinberger,
2005; Konradi and Heckers, 2003).
*Correspondence to: Philip W.J. Burnet, Department of Psychiatry, Univer-
sity of Oxford, Warneford Hospital, Oxford OX3 7JX, United Kingdom.
E-mail: phil.burnet@psych.ox.ac.uk
Received 1 February 2008; Revised 28 March 2008; Accepted 8 April 2008
DOI 10.1002/syn.20553
Published online in Wiley InterScience (www.interscience.wiley.com).
V V C 2008 WILEY-LISS, INC.
SYNAPSE 62:842–850 (2008)Given these ﬁndings, it becomes important to dis-
tinguish the properties of mGluR2 from those of
mGluR3, a distinction that has been hampered by the
lack of adequately selective ligands and antibodies.
Nevertheless, several differences are known (for
review, see Harrison et al., in press), including cellu-
lar and subcellular localization (Tamaru et al., 2001),
expression proﬁle across brain development (Catania
et al., 1994), the presence of splice variants (Sartorius
et al., 2006), and interactions with protein phospha-
tase 2C (Flajolet et al., 2003). These ﬁndings are com-
plemented recently by data in mGluR2
 /  and
mGluR3
 /  mice. For example, mGluR2
 /  mice show
reduced mossy ﬁber long-term depression (Yokoi
et al., 1996) and locomotor hyperactivity (Morishima
et al., 2005), whereas mGluR3
 /  mice show en-
hanced hippocampal c-Fos expression (Linden et al.,
2006) and vulnerability to NMDA-induced neurotoxic-
ity (Corti et al., 2007b). However, conclusions drawn
from knockout mice may be complicated by secondary
changes in expression of other genes, which may com-
pensate for, enhance, or otherwise modify, the effect
of the gene deletion. Currently, the molecular pheno-
types of mGluR2
 /  and mGluR3
 /  mice remain
unknown. This study has therefore examined the
expression of key genes involved in glutamatergic
neurotransmission in both knockout mice compared
with their respective wild-type littermates. We
focused on the hippocampus, as a structure critically
involved in schizophrenia (Harrison, 2004) and cogni-
tion (Martin and Clark, 2007; Sweatt, 2004), and in
which mGluR function has previously been examined
in detail. The targeted genes included the remaining
group II mGluR, to assess the possibility of compensa-
tory upregulation, as well as NMDA receptors (NR1,
NR2A, NR2B subunits) and glutamate transporters
(EAAT1 [GLAST], EAAT2 [GLT-1], and EAAT3
[EAAC1]). These receptors and transporters were
measured because there is already pharmacological
evidence linking them with mGluR2 and/or mGluR3
(e.g., Aronica et al., 2003; Cartmell et al., 1999; Gege-
lashvili et al., 2000; Krystal et al., 2005; Moghaddam
and Adams, 1998), and we predicted a change in their
expression as a correlate of the altered glutamate sig-
naling characteristics that likely accompany the
genetic deletion of a group II mGluR. In each case,
quantiﬁcation of the encoding mRNA by in situ
hybridization was used; in the case of EAAT1 and
EAAT2 we complemented these results with immu-
noautoradiographic assessment of the protein. Our
results show that deletion of mGluR2 or mGluR3 pro-
duces similar but not identical effects on expression
of these glutamatergic genes, and illustrate the
importance of both group II mGluRs in hippocampal
glutamate signaling and thence, presumably, in hip-
pocampal functioning. Some of the data have been
presented in abstracts (Lyon et al., 2006, 2007).
MATERIALS AND METHODS
Animals and tissue sectioning
mGluR2
 /  and mGluR3
 /  mice were generated on
a C57Bl/6 3 129SVj background, as described (Corti
et al., 2004, 2007a; Yokoi et al., 1996). Brains from
six male 12-week-old mGluR2
 /  mice and six wild-
type littermates, plus six male 12-week-old mGluR3
 / 
mice and six wild-type littermates, were snap frozen
by immersion in chilled isopentane. Brains were
stored at  808C. Unﬁxed coronal sections (12 lm)
containing the dorsal hippocampus were collected on
a Shandon cryostat at  208C. Sections were collected
on Superfrost Plus slides (VWR, Lutterworth, UK),
three per slide, and stored at  708C.
In situ hybridization histochemistry
In situ hybridization histochemistry was carried
out as described by Eastwood et al. (2007). Pretreat-
ment consisted of: freshly prepared 4% paraformalde-
hyde in phosphate-buffered saline (PBS) (5 min); PBS
(rinse); 0.1 M triethanolamine-NaCl solution contain-
ing 0.25% acetic anhydride added immediately prior
to use (10 min); 70% ethanol (1 min); 80% ethanol (1
min); 95% ethanol (2 min); 100% ethanol (1 min);
chloroform (10 min); 100% ethanol (1 min); 95% etha-
nol (1 min). Sections were air-dried and stored at
 208C. Oligonucleotide probes were synthesized
(Sigma, Dorset, UK) (Table I) and 30 end-labeled with
[
35S]dATP using the enzyme terminal deoxynucleoti-
dyl transferase (TdT) (Promega, Southampton, UK).
Labeled probe was puriﬁed from unincorporated nu-
cleotides using Nick Columns (Amersham, Bucks,
UK) according to manufacturer’s instructions. Sec-
tions were incubated overnight at 358C in 225 ll
hybridization buffer [43 sodium saline citrate (SSC),
50% deionized formamide, 10% dextran sulfate, 25
mM sodium phosphate (pH 7.0), 53 Denhardt’s solu-
tion, 200 lg/ml salmon sperm DNA, 100 lg/ml
poly(A), 1 mM sodium pyrophosphate, 120 lg/ml hep-
arin] containing 33 10
6 counts per minute of labeled
probe and 20 mM dithiothreitol. Posthybridization
washes were conducted in 13 SSC for 33 20 min at
558C, followed by 23 60 min at room temperature.
Hybridized sections were apposed to Kodak Biomax
MS ﬁlm together with
14C microscales (GE Health-
care, Little Chalfont, UK) for an optimal length of
time determined by trial experiments (Table I).
Immunoautoradiography
Sections were ﬁxed in 4% paraformaldehyde/PBS
for 5 min, and then washed twice in PBS. Nonspeciﬁc
binding was blocked by incubating the slides in
200 ll of normal donkey serum (Sigma, Dorset, UK),
diluted 1:10 in PBS with 0.3% Triton X-100 (PBS-T),
for 30 min at room temperature. Sections were incu-
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EAAT1 (Abcam, Cambridge, UK) diluted 1:200 in
PBS-T, or with rabbit polyclonal anti-EAAT2 (Abcam)
diluted 1:200 with PBS-T. Omission of primary anti-
body was used as a control. After three PBS washes
to remove unbound primary, sections were incubated
with 0.2 lCi/ml [
35S]-labeled donkey antirabbit IgG
(Amersham) at 1:500 in PBS-T and 1% donkey serum,
for 1 h at room temperature. Following washes in
PBS and MilliQ Ultrapure water to remove unbound
secondary, slides were left to air-dry, before being
placed against Kodak Biomax MS ﬁlm with
14C
microscales for 7 days.
Image and statistical analysis
Autoradiographic ﬁlms were developed under safe-
light conditions and measured using the MCID Elite
v7.0 image analysis system (Interfocus, Haverhill,
UK). Optical density values were calibrated to
35SnCi/g tissue equivalents using the
14C microscales.
In the case of the neuronally expressed mRNAs,
namely EAAT3 and the NMDAR subunits, measure-
ments were taken over the stratum granulosum of
the dentate gyrus, and over the stratum pyramidale
of CA3 and CA1 subﬁelds. In contrast, EAAT1 and
EAAT2 mRNA and immunoreactivity were measured
over a broadband distributed across the various
strata of each subﬁeld, reﬂecting the diffuse localiza-
tion of these glial-expressed genes.
All data were explored for normality using the Kol-
mogorov–Smirnov test (in SPSS for Windows, v15.0).
Group differences (knockout vs. wild-type) in the hip-
pocampal expression of each gene were analyzed
using ANOVA across all subﬁelds examined; if a sig-
niﬁcant effect of genotype or genotype-by-subﬁeld
interactions were observed, separate analyses were
performed in each subﬁeld. Experiments on the
mGluR2
 /  and mGluR3
 /  mice were conducted at
different times (and compared with separate control
groups), and were therefore analyzed separately.
RESULTS
The regional hippocampal distribution of each tran-
script was as reported previously: mGluR2 (Ohishi
et al., 1993a), mGluR3 (Ohishi et al., 1993b), EAAT1
and EAAT2 (Ingram et al., 2001), EAAT3 (Kanai and
Hediger, 1992), and NMDAR subunits (Monyer et al.,
1992). Hybridization in the presence of excess unla-
beled probe produced minimal background signal (not
shown). The distribution of EAAT1 (Schmitt et al.,
1997) and EAAT2 (Rothstein et al., 1994) immunor-
eactivity was also in agreement with previous ﬁnd-
ings and western blotting conﬁrmed that the antibod-
ies we used produced a single band of the expected
 65 kDa (EAAT1) and  73 kDa (EAAT2) in mouse
brain (data not shown).
mGluR2 and mGluR3 mRNA
Hybridization signals for mGluR2 (Fig. 1A) and
mGluR3 (Fig. 1B) mRNA were present mainly over
the dentate gyrus, and were only quantiﬁed over this
subﬁeld.
mGluR2 mRNA
mGluR2 mRNA was increased in the mGluR3
 / 
mice compared with their wild-type littermates (F(1,10)
5 14.81; P 5 0.003; Figs. 1A and 2A).
mGluR3 mRNA
mGluR3 mRNA was increased in the mGluR2
 / 
mice compared with their wild-type littermates (F(1,6)
5 23.14; P 5 0.003) (Figs. 1B and 2B).
Glutamate transporter mRNAs
EAAT1 (GLAST) mRNA
For EAAT1 mRNA, in mGluR2
 /  mice there was
no effect of genotype and no genotype-by-subﬁeld
interaction (both F < 1, P > 0.20). By contrast,
mGluR3
 /  mice showed a main effect of genotype
(F(1,20) 5 15.22; P < 0.001) as well as a trend geno-
type-by-subﬁeld interaction (F(1,20) 5 3.68; P 5
0.070). Subsequent analysis revealed that EAAT1
mRNA was reduced in both the dentate gyrus (F(1,10)
5 9.77; P 5 0.011) and CA1 (F(1,10) 5 7.38; P 5
0.022) of mGluR3
 /  mice compared with their wild-
type littermates (Table II; Fig. 1C).
TABLE I. Nucleotide sequences of probes used for in situ hybridization histochemistry, and exposure times against autoradiographic ﬁlm
Gene GenBank accession number Oligodeoxynucleotide sequence (50 to 30)
Exposure
time (days)
mGluR2 XM_001475814.1 GGT GAA GAG CAC AGC CAC ACG GGC GCT GGG CTT CT 12
mGluR3 NM_181850.2 TTG CCA CCT GTA TGG AAA CAC TGC TGT ACG AAC CC 21
EAAT1 NM_148938.2 GTA GTA GTC ATG TAA TAG ACT ACA GCG CGC ATC CCC 12
EAAT2 NM_011393.2 GTA CCT TGC ACT CAT CTA TTA CGA CAG AGT TGT GT 5
EAAT3 NM_009199.2 TAG TGA GTT CCA GGA TAT CCA GGG CTA TGT AGA GA 4
NR1 NM_008169 GTA GAC CTG GCT GGA GAT GAG GTC CTC GCA CAC CGA CAG AGC CAT 4
NR2A NM_008170 AGA AGG CCC GTG GGA GCT TTC CCT TTG GCT AAG TTTC 4
NR2B NM_008171.3 GGG CCT CCT GGC TCT CTG CCA TCG GCT AGG CAC CTG TTG TAA CCC 8
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For EAAT2 mRNA there was no effect of genotype
or no genotype-by-subﬁeld interaction, in either
mGluR2
 /  or mGluR3
 /  mice (all F < 1, P > 0.20)
(Table II; Fig. 1D).
EAAT3 (EAAC1) mRNA
In mGluR2
 /  mice, EAAT3 mRNA showed a main
effect of genotype (F(1,21) 5 14.80; P < 0.001) but no
interaction with subﬁeld (F < 1; P > 0.20). One-way
ANOVA conﬁrmed that EAAT3 mRNA was reduced
Fig. 1. A: mGluR2 mRNA distribution in wild types (left-hand
panel); mGluR2 mRNA signal is increased in mGluR3
 /  mice
(right-hand panel). B: mGluR3 mRNA in wild types (left); mGluR3
mRNA is increased in mGluR2
 /  mice (right). C: EAAT1 (GLAST)
mRNA in wild types (left); EAAT1 (GLAST) mRNA is decreased in
mGluR3
 /  mice (right). D: EAAT2 (GLT-1) mRNA in wild types
(left); EAAT2 (GLT-1) mRNA is unchanged in mGluR3
 /  mice
(right) and in mGluR2
 /  mice (not shown). E: EAAT3 (EAAC1)
mRNA in wild types (left); EAAT3 (EAAC1) mRNA is decreased in
mGluR2
 /  mice (right). F: NR2A mRNA in wild types (left); NR2A
mRNA is increased in mGluR2
 /  mice (right) and in mGluR3
 / 
mice (not shown). G: EAAT1 (GLAST) protein in wild types (left);
EAAT1 (GLAST) protein is decreased in mGluR3
 /  mice (right). H:
EAAT2 (GLT-1) protein in wild types (left); EAAT2 (GLT-1) protein
is decreased in mGluR3
 /  mice (right) and in mGluR2
 /  mice (not
shown). Inset panels display hippocampal enlargements.
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 /  hippocampus, signiﬁcantly
in CA1 (F(1,7) 5 13.27; P 5 0.008) and at trend signiﬁ-
cance in dentate gyrus (F(1,7) 5 4.69; P 5 0.067) and
CA3 (F(1,7) 5 3.98; P 5 0.086) (Fig. 3E). EAAT3
mRNA was unaltered in mGluR3
 /  mice, with no
effect of genotype and no genotype-by-subﬁeld inter-
action (both F < 1; P > 0.20) (Table II).
Glutamate transporter proteins
EAAT1 (GLAST)
Results for EAAT1 immunoreactivity were similar
to those for EAAT1 mRNA. Thus, in mGluR2
 /  mice,
there was no effect of genotype and no genotype-by-
subﬁeld interaction (both F < 1; P > 0.20). In
mGluR3
 /  animals, there was an effect of genotype
(F(1,20) 5 15.62; P 5 0.001), but no genotype-by-sub-
ﬁeld interaction (F < 1; P > 0.20). EAAT1 immunor-
eactivity was reduced in a fairly uniform manner
throughout the mGluR3
 /  hippocampus (dentate
gyrus: F(1,10) 5 7.60; P 5 0.02; CA1: F(1,10) 5 8.03; P
5 0.018) (Table II; Fig. 1G).
EAAT2 (GLT-1)
EAAT2 immunoreactivity was not changed in
mGluR2
 /  animals, with no effect of genotype, and
no genotype-by-subﬁeld interaction (both F < 1; P >
0.20). In mGluR3
 /  animals, by contrast, there was
a main effect of genotype (F(1,30) 5 24.78; P < 0.001)
although no genotype-by-subﬁeld interaction (F < 1;
P > 0.20). Consistent with these ﬁndings, EAAT2
immunoreactivity was reduced in all subﬁelds of the
mGluR3
 /  hippocampus (dentate gyrus: F(1,10) 5
5.98; P 5 0.035; CA3: F(1,10) 5 5.86; P 5 0.036; CA1:
F(1,10) 5 15.60; P 5 0.003) (Table II; Fig. 1H).
NMDA receptor subunit mRNAs
NR1 mRNA
In mGluR2
 /  mice, there was no effect of genotype
on NR1 mRNA (F < 1; P > 0.20) but there was a ge-
notype-by-subﬁeld interaction (F(2,27) 5 3.98; P 5
0.033). The latter reﬂected a small decrease in the
knockouts in CA3 and an increase in CA1; however,
neither change was signiﬁcant in the post hoc test
(CA3: F(1,9) 5 2.97; P 5 0.119; CA1: F(1,9) 5 2.86; P 5
0.125). NR1 mRNA was unaltered in mGluR3
 / 
mice, with no effect of genotype or no genotype-by-
subﬁeld interaction (both F < 1, P > 0.2) (Table II).
NR2A mRNA
In mGluR2
 /  mice, there was an effect of genotype
on NR2A mRNA (F(1,26) 5 4.44; P 5 0.045), but no
interaction with subﬁeld (F(2,26) 5 2.09; P 5 0.145).
One-way ANOVA conﬁrmed that NR2A mRNA was
increased in the dentate gyrus (F(1,8) 5 10.17; P 5
0.013), but not signiﬁcantly in CA3 or CA1 (both F <
1; P > 0.20) (Table II; Figs. 1F and 3A). In mGluR3
 / 
mice, there was again a main effect of genotype for
NR2A mRNA (F(1,27) 5 11.14; P 5 0.002), but no ge-
notype-by-subﬁeld interaction (F < 1; P > 0.20). Post
hoc tests showed NR2A mRNA increased in the den-
tate gyrus (F(1,9) 5 5.73; P 5 0.04) and CA3 (F(1,9) 5
5.35; P 5 0.046) but not CA1 (F(1,9) 5 1.89; P 5
0.203) of mGluR3
 /  mice (Table II; Fig. 3B).
NR2B mRNA
NR2B mRNA was unchanged in both knockout
mice (all F < 1.7; P > 0.20) (Table II).
DISCUSSION
Determining the individual properties of the two
group II mGluRs, mGluR2 and mGluR3, has been
problematic because of a dearth of suitable selective
ligands and antibodies. The generation of mGluR2
 / 
and mGluR3
 /  mice has therefore been an important
step forward. Use of these mice has, for example,
showed a prominent role for mGluR2 in mossy ﬁber
long term depression (Yokoi et al., 1996) and for
mGluR3 in neuroprotection (Corti et al., 2007b), and
for both receptors in the anxiolytic response to a
mGluR2/3 agonist (Linden et al., 2005). However,
Fig. 2. mGluR2 mRNA (A) is increased in the dentate gyrus of
mGluR3
 /  mice (n 5 6) compared to wild types (n 5 6), whereas
mGluR3 mRNA (B) is increased in the dentate gyrus of mGluR2
 / 
mice (n 5 4) compared to wild types (n 5 4).
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sion of the surviving group II mGluR, or indeed
expression of other genes involved in glutamate neu-
rotransmission, is altered in each knockout mouse.
Such information is clearly relevant when interpret-
ing their phenotype and extrapolating to the func-
tion(s) of the receptors. Here, in parallel experiments,
we have studied the hippocampal expression of seven
glutamatergic transcripts, and two of the encoded
proteins, in mGluR2
 /  and mGluR3
 /  mice. Our
results show that knockout of either gene leads to
upregulation of the remaining group II mGluR and
upregulation of the NR2A subunit of the NMDA re-
ceptor, as well as to downregulation of glutamate
transporters. However, the identity of the affected
transporter differs between the mice: loss of mGluR2
leads to a decrease of the neuronal EAAT3, whereas
deletion of mGluR3 results in reduction of the glial
transporters EAAT1 and EAAT2.
A notable ﬁnding was the increase of mGluR3
expression in mGluR2
 /  mice, and vice versa, which
suggests a mutual—albeit partial—compensatory
response to the loss of a group II mGluR, which may
contribute to the relatively mild behavioral phenotype
seen in both mice, particularly mGluR3 knockouts.
Equally, the increase was only modest in percentage
terms, which may explain why deletion of either gene
Fig. 3. NR2A mRNA is increased in the hippocampus of both
(A) mGluR2
 /  (n 5 6) compared to wild type (n 5 6) and (B)
mGluR3
 /  (n 5 5) compared to wild type (n 5 5) mice.
TABLE II. Hippocampal expression of EAAT1 (GLAST) mRNA and protein, EAAT2 (GLT-1) mRNA and protein, EAAT3 (EAAC1) mRNA,
and NR1, NR2A, and NR2B mRNA in mGluR2
 /  and mGluR3
 /  mice
Gene
mGluR2 mGluR3
wt (n 5 5) ko (n 5 4-6) wt (n 5 6) ko (n 5 6)
EAAT1 mRNA
a DG 279 6 13 264 6 17 259 6 14 210 6 7*
CA1 159 6 51 5 9 6 11 142 6 51 2 5 6 4*
protein
b DG 1210 6 123 1206 6 75 453 6 22 375 6 18*
CA1 1343 6 92 1283 6 85 460 6 26 372 6 18*
EAAT2 mRNA DG 1357 6 99 1339 6 51 1425 6 88 1479 6 100
CA3 2455 6 29 2588 6 72 2141 6 151 2147 6 187
CA1 956 6 44 944 6 32 745 6 40 722 6 49
protein
c DG 1160 6 67 1259 6 42 1733 6 58 1542 6 53*
CA3 1037 6 62 1070 6 24 1591 6 42 1454 6 38*
CA1 1081 6 33 1087 6 54 1699 6 51 1459 6 43**
EAAT3 mRNA
d DG 3148 6 351 2046 6 362 2579 6 276 2684 6 229
CA3 1612 6 282 941 6 122 1652 6 286 1746 6 252
CA1 1741 6 144 1058 6 104** 1917 6 277 1990 6 253
NR1 mRNA
e DG 1449 6 45 1539 6 49 1485 6 68 1534 6 48
CA3 1454 6 78 1289 6 47 1337 6 77 1456 6 33
CA1 1377 6 58 1554 6 92 1535 6 65 1593 6 37
NR2A mRNA
f,g DG 811 6 17 1011 6 49* 1326 6 34 1507 6 53*
CA3 723 6 55 693 6 49 1061 6 34 1172 6 33*
CA1 979 6 65 1104 6 71 1467 6 69 1611 6 80
NR2B mRNA DG 913 6 26 948 6 31 1087 6 45 1037 6 20
CA3 840 6 40 784 6 54 912 6 30 886 6 37
CA1 1111 6 42 1184 6 20 1344 6 80 1378 6 54
Values are mean
35SnCi/g tissue equivalents 6 SEM.
wt, wild type; ko, knockout.
aMain effect of genotype in mGluR3
 /  mice, P < 0.001 (univariate ANOVA).
bMain effect of genotype in mGluR3
 /  mice, P 5 0.001 (univariate ANOVA).
cMain effect of genotype in mGluR3
 /  mice, P < 0.001 (univariate ANOVA).
dMain effect of genotype in mGluR2
 /  mice, P < 0.001 (univariate ANOVA).
eGenotype by subﬁeld interaction in mGluR2
 /  mice, P 5 0.033 (univariate ANOVA).
fMain effect of genotype in mGluR2
 /  mice, P 5 0.045 (univariate ANOVA).
gMain effect of genotype in mGluR3
 /  mice, P 5 0.002 (univariate ANOVA).
*P < 0.05, **P < 0.01, post-hoc comparisons (one-way ANOVA).
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behavioral consequences (for review, see Harrison
et al., in press). Complementary studies of the
encoded proteins will be needed to conﬁrm the local-
ization and magnitude of the reciprocal upregulation.
Group II mGluRs have complex interactions with,
and effects upon, NMDA receptors (Moghaddam and
Adams, 1998), and it is thus of interest that, in both
mGluR2
 /  and mGluR3
 /  mice, the NR2A subunit
was selectively upregulated, with no alteration in ei-
ther NR1 or NR2B subunit mRNAs. This ﬁnding fol-
lows a previous report that the mGluR2/3 agonist
APDC enhances NMDA-evoked responses in dissoci-
ated rat prefrontal cortex neurons, predominantly via
NR2A-containing receptors (Tyszkiewicz et al., 2004).
Our data imply that an increased proportion of hippo-
campal NMDARs in mGluR2
 /  and mGluR3
 /  mice
contain an NR2A rather than NR2B subunit. This dif-
ference will likely inﬂuence their properties in several
ways, including calcium ﬂux and channel opening
kinetics, postsynaptic protein coupling, and perhaps
long-term potentiation (Cull-Candy et al., 2001; Liu
et al., 2004; Monyer et al., 1994; Sheng et al., 2000).
The net functional effect of a more ‘‘NR2A-dominant’’
NMDA receptor population, in the presence of a lack
of one or other group II mGluR, remains to be deter-
mined and will beneﬁt from electrophysiological
approaches.
A major role of group II mGluRs, especially
mGluR2, is as inhibitory autoreceptors (Anwyl, 1999;
Cartmell and Schoepp, 2000; Kew et al., 2002). Our
results show that one consequence of deletion of ei-
ther receptor is a downregulation of glutamate trans-
porter expression. This presumably is a response to
an altered level of synaptic or extra-synaptic gluta-
mate, in turn supporting the role in vivo of both
receptors in regulating synaptic glutamate release.
However, three points regarding the altered EAAT
expression are noteworthy. The ﬁrst concerns the
direction of effect. Simplistically, the loss of a group II
mGluR might be predicted to increase glutamate
release and thence extracellular glutamate levels, and
hence that the transporters might be upregulated as
part of a homeostatic response, as has been suggested
for EAAT1 in cortical astrocytes (Gegelashvili et al.,
1996). On the other hand, our ﬁnding is consistent
with Aronica et al. (2003), who showed that mGluR3
activation increases glial glutamate transporter
expression in vitro. These diverse ﬁndings emphasize
that the regulation of EAAT expression and activity
are complex and incompletely understood (Gegelash-
vili and Schousboe, 1997; Shigeri et al., 2004), and so
until the effect of group II mGluR deletion on gluta-
mate release and/or extracellular glutamate levels is
known, it will remain difﬁcult to interpret the cause
and signiﬁcance of the decreased glutamate trans-
porter expression observed here.
The second point concerns the identity of the spe-
ciﬁc transporters affected in the two mouse lines. The
glial glutamate transporters EAAT1 and EAAT2 were
downregulated in mGluR3
 /  mice but unchanged in
mGluR2
 /  mice. In contrast, the neuronal glutamate
transporter EAAT3 was reduced in the mGluR2
knockouts but unchanged in their mGluR3
 /  coun-
terparts. It is tempting to relate this proﬁle to the
fact that mGluR2 is exclusively neuronally expressed
(Shigemoto et al., 1997), whereas mGluR3 is promi-
nently and additionally expressed in astrocytes and
other glial subtypes (Wroblewska et al., 1998). It is
also of note that, in human brain, polymorphic varia-
tion in mGluR3 impacts on EAAT2 expression (Egan
et al., 2004). Third, while EAAT1 mRNA and protein
levels were both reduced, EAAT2 protein alone was
downregulated, with EAAT2 mRNA remaining
unchanged. This supports other studies showing that
EAAT2 expression is regulated primarily at the trans-
lational level (Gegelashvili and Schousboe, 1997; Tian
et al., 2007).
In summary, this study has shown that deletion of
either mGluR2 or mGluR3 genes produces changes in
the hippocampal expression of several other genes
involved in glutamatergic neurotransmission. Such
changes should be considered when interpreting the
phenotype of the mice in behavioral, electrophysiolog-
ical, and pharmacological studies. The fact that the
changes are broadly similar in both mice is consistent
with the grouping of mGluR2 and mGluR3 together
as group II mGluRs, and for a signiﬁcant overlap in
their functional roles. Equally, the distinct proﬁle of
glutamate transporter alterations in mGluR2
 /  vs.
mGluR3
 /  mice supports the emerging evidence for
speciﬁc differences in the expression and properties of
the two receptors (Corti et al., 2007b; Harrison et al.,
in press). Further studies need to include other brain
regions, developmental stages, and additional tran-
scripts and proteins. In particular, the expression of
other glutamate receptors, most notably AMPAR sub-
units and additional presynaptic mGluRs, could use-
fully be examined. The continuing dissection of the
molecular phenotype of mGluR2
 /  and mGluR3
 / 
mice will contribute to the understanding of the rela-
tive contribution of each receptor in the aetiopatho-
genesis and pharmacotherapy of schizophrenia and
other psychiatric disorders in which they are increas-
ingly implicated.
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